表阿霉素与环磷酰胺两种剂量水平与经典CMF方案治疗淋巴结阳性乳腺癌的比较。一项辅助性III期试验 - Suppr | 超能文献

[Comparison of epirubicin and cyclophosphamide in 2-dose levels and classical CMF protocol in node-positive breast cancer. An adjuvant Phase III trial].

作者信息

Ost E, Illiger H J

出版信息

Strahlenther Onkol. 2002 Jan;178(1):54-5.

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

[Comparison of epirubicin and cyclophosphamide in 2-dose levels and classical CMF protocol in node-positive breast cancer. An adjuvant Phase III trial].表阿霉素与环磷酰胺两种剂量水平与经典CMF方案治疗淋巴结阳性乳腺癌的比较。一项辅助性III期试验

Strahlenther Onkol. 2002 Jan;178(1):54-5.

2

Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1-3 node-positive rapidly proliferating breast cancer.随机 III 期试验：辅助表柔比星继以环磷酰胺、甲氨蝶呤和 5-氟尿嘧啶（CMF）与 CMF 继以表柔比星治疗淋巴结阴性或 1-3 个淋巴结阳性快速增殖型乳腺癌患者。

Breast Cancer Res Treat. 2011 Feb;125(3):775-84. doi: 10.1007/s10549-010-1257-5. Epub 2010 Dec 4.

3

Long-term benefit of high-dose epirubicin in adjuvant chemotherapy for node-positive breast cancer: 15-year efficacy results of the Belgian multicentre study.高剂量表柔比星在淋巴结阳性乳腺癌辅助化疗中的长期获益：比利时多中心研究的15年疗效结果

J Clin Oncol. 2009 Feb 10;27(5):720-5. doi: 10.1200/JCO.2008.17.2155. Epub 2008 Dec 22.

4

[Radiation and concomitant chemotherapy after surgery for breast cancer].[乳腺癌手术后的放疗与同步化疗]

Cancer Radiother. 2004 Feb;8(1):39-47. doi: 10.1016/j.canrad.2003.10.010.

5

Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5.比较环磷酰胺、表柔比星和氟尿嘧啶与环磷酰胺、甲氨蝶呤和氟尿嘧啶用于绝经前淋巴结阳性乳腺癌女性的随机试验：加拿大国家癌症研究所临床试验组MA5试验的更新

J Clin Oncol. 2005 Aug 1;23(22):5166-70. doi: 10.1200/JCO.2005.09.423.

6

[Sequencing of chemotherapy and radiotherapy following breast-preserving treatment of breast carcinoma].乳腺癌保乳治疗后化疗与放疗的序贯治疗

Strahlenther Onkol. 1996 Sep;172(9):516-7.

7

Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement.高剂量化疗及造血祖细胞支持用于伴有广泛腋窝淋巴结受累的可手术乳腺癌的随机试验

Lancet. 1998 Aug 15;352(9127):515-21. doi: 10.1016/S0140-6736(98)01350-6.

8

Treatment of advanced breast cancer: How much chemotherapy is enough?晚期乳腺癌的治疗：多少化疗剂量才足够？

Semin Oncol. 1996 Jun;23(3):xv-xxii; discussion xxii-xxiv.

9

Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma.一项随机试验，比较环磷酰胺、甲氨蝶呤和5-氟尿嘧啶（CMF）与交替使用CMF、表柔比星和长春新碱作为可手术乳腺癌的一线化疗方案。

Cancer. 2002 Jul 15;95(2):228-35. doi: 10.1002/cncr.10678.

10

Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: a report from the National Cancer Institute of Canada Clinical Trials Group.表柔比星辅助化疗后急性白血病的风险：来自加拿大国家癌症研究所临床试验组的报告

J Clin Oncol. 2003 Aug 15;21(16):3066-71. doi: 10.1200/JCO.2003.08.137.